Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference.
Myeloid cells, originating from bone marrow and exhibiting high plasticity, play a crucial role in cancer, especially in forming tumour-associated macrophages that suppress immunity within tumours. Faron's innovative approach involves reprogramming these cells to support the immune system instead of cancer cells, potentially leading to an immune system attack against cancer cells.
The company's leading product, an antibody named Bexmarilimab, demonstrates promising results in controlling tumour environments in solid and haematological cancers. Jalkanen highlighted Bexmarilimab's exceptional safety profile and its ability to convert immunosuppressive macrophages into immune activators. The treatment has shown a significant increase in overall survival rates in cancer patients, particularly in those with no other treatment options.
Faron Pharmaceuticals has patent protection until 2037 and has garnered significant interest from big pharma companies. The company is also exploring the potential of Bexmarilimab in treating myeloid leukemia by targeting the Clever-1 molecule on cancerous cells, disrupting their energy production, and reducing their viability.
Dr. Jalkanen emphasised the impressive clinical trial results, including a 100% response rate in high-risk myeloid dysplastic syndrome (MDS) patients. The company is now focusing on this patient group, recognising the substantial market opportunity. The trials are ongoing, with expansion plans in the U.S. and Europe.
